Immunotherapy combinations for the treatment of patients with solid tumors
- PMID: 32501724
- DOI: 10.2217/fon-2020-0303
Immunotherapy combinations for the treatment of patients with solid tumors
Abstract
Immune checkpoint inhibitors directed against CTLA-4, PD-1 and PD-L1 have transformed the treatment of patients with cancer. Immunotherapy regimens have evolved from a single agent approach to the combination of immune checkpoint inhibitors like anti CTLA-4 and PD-1, immune checkpoint blockade combined with chemotherapy, anti-angiogenic agents and kinase inhibitors. These synergistic combinations were developed to heighten the potency and duration of immune responses against cancer cells. Hence, immunotherapy combinations have shaped the landscape of therapeutic options against a wide range of cancer types, and are current standard treatment regimens worldwide. In this review, we describe the clinical evidence supporting the use of immunotherapy combination regimens for the treatment of patients with solid tumors.
Keywords: anti-angiogenesis; chemotherapy; combination; immunotherapy; kinase inhibitor.
Similar articles
-
Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors.Curr Oncol Rep. 2021 Jul 16;23(9):100. doi: 10.1007/s11912-021-01099-7. Curr Oncol Rep. 2021. PMID: 34269922 Review.
-
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.BMC Cancer. 2021 Apr 17;21(1):425. doi: 10.1186/s12885-021-08165-0. BMC Cancer. 2021. PMID: 33865350 Free PMC article.
-
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.Front Immunol. 2020 Aug 25;11:1956. doi: 10.3389/fimmu.2020.01956. eCollection 2020. Front Immunol. 2020. PMID: 32983126 Free PMC article. Review.
-
Atypical patterns of response and progression in the era of immunotherapy combinations.Future Oncol. 2020 Aug;16(23):1707-1713. doi: 10.2217/fon-2020-0186. Epub 2020 Jul 20. Future Oncol. 2020. PMID: 32687405
-
Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery perspective).Future Oncol. 2020 Aug;16(23):1677-1681. doi: 10.2217/fon-2020-0171. Epub 2020 May 14. Future Oncol. 2020. PMID: 32407147 No abstract available.
Cited by
-
Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity.Mol Ther Oncolytics. 2021 Nov 29;24:1-13. doi: 10.1016/j.omto.2021.11.017. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2021. PMID: 34977338 Free PMC article.
-
CD11b+DIP2A+LAG3+ cells facilitate immune dysfunction in colorectal cancer.Am J Cancer Res. 2021 Nov 15;11(11):5428-5439. eCollection 2021. Am J Cancer Res. 2021. PMID: 34873470 Free PMC article.
-
Nanotechnology-enhanced immunotherapy for metastatic cancer.Innovation (Camb). 2021 Oct 14;2(4):100174. doi: 10.1016/j.xinn.2021.100174. eCollection 2021 Nov 28. Innovation (Camb). 2021. PMID: 34766099 Free PMC article. Review.
-
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.Int J Mol Sci. 2021 Apr 5;22(7):3765. doi: 10.3390/ijms22073765. Int J Mol Sci. 2021. PMID: 33916438 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
